Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|April 6, 1994

Serviscope's Southard to step down

Serviscope president and CEODonald J. Southard will be leaving the independent service organizationas part of a move to refocus the company's direction. Also leavingthe Wallingford, CT, company is vice president Robert Cate. Serviscope expanded rapidly

Serviscope president and CEODonald J. Southard will be leaving the independent service organizationas part of a move to refocus the company's direction. Also leavingthe Wallingford, CT, company is vice president Robert Cate.

Serviscope expanded rapidly under Southard's tenure but hasconsumed cash almost as quickly, requiring several rounds of privateequity financing. Serviscope hopes that a change at the top willstrengthen the financial management of the company, accordingto Emile Geisenheimer, the company's chairman and a general partnerof Nazem & Co., a venture capital firm that holds a majoritystake in Serviscope.

"The company has grown dramatically over the last severalyears," Geisenheimer said. "Don has done a terrificjob in the sales and marketing arena, but we need to add strengthin (financial management)."

Serviscope has grown from four customers in 1990 to 630 lastyear. The company's revenues have risen accordingly, increasingfrom $100,000 in its first year to $13 million in 1993 (end-September).Serviscope is on a pace to bring in $20 million this year, andthe ISO turned profitable in the first quarter of 1994, accordingto Geisenheimer.

Southard joined Serviscope in 1991 after working for OEMs Philipsand Toshiba (SCAN 12/25/91). He will remain on Serviscope's boardof directors and will provide consulting to the ISO, accordingto Geisenheimer, who is also a former Philips medical executive.

Serviscope is negotiating with an unnamed medical imaging managerto take over the top spot, Geisenheimer said.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.